Connect with us

Finance

RFK Jr. is a ‘conspiracy theorist’ endangering lives, say analysts at Howard Lutnick’s former firm

Published

on

US President Donald Trump speaks to the press before signing an Executive Order, alongside US Secretary of Health and Human Services Robert F. Kennedy Jr. (L) and US Secretary of Commerce nominee Howard Lutnick (R), at the Oval Office of the White House in Washington, DC on Feb. 25, 2025. 

Jim Watson | AFP | Getty Images

Health and Human Services Secretary Robert F. Kennedy Jr., an anti-vaccine crusader, is not qualified to have any power at the agency that’s supposed to protect the health of Americans, said research analysts at Cantor Fitzgerald, which was formerly headed by Commerce Secretary Howard Lutnick.

Cantor’s note came as Peter Marks, the head of the FDA biologics division, resigned in protest of Kennedy’s skepticism of vaccines. Kennedy, a prominent vaccine skeptic, has already taken steps that public health experts say could deter routine immunizations in the U.S.

“We call on the administration to re-evaluate RFK Jr’s role at HHS. Pushing out one of the most trusted leaders of the FDA to promote an anti-science agenda is a step too far for us,” analysts Josh Schimmer and Eric Schmidt wrote in an unusual note to clients Tuesday. “HHS cannot be led by an anti-vax, conspiracy theorist with inadequate training.”

Kennedy has downplayed the importance of the measles, mumps and rubella vaccine and promoted unproven treatments to counter the measles outbreak. The Centers for Disease Control and Prevention is also carrying out a study into long debunked links between vaccines and autism, led by a researcher with a history of spreading misinformation about shots.

“An amateur scientist who doesn’t appreciate the need for difficult public health policy decisions, who struggles with the difference between causality and correlation, and who promotes unproven remedies at the expense of proven ones is not the right person for the job, on our view,” Cantor analysts wrote.

Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, sold off significantly Monday after the resignation of Marks. Moderna and Novavax both shed more than 8%, while the SPDR S&P Biotech ETF slid nearly 4%.

“This has nothing to do with stocks, although the biotech tape may be roiled from Marks’ resignation, that’s not what matters,” stated the analysts who normally opine to clients about whether to buy or sell certain equities. “This is much bigger than that.”

HHS didn’t immediately respond to a CNBC’s request for comment.

“We already had a needless measles death. It’s time to end the narrative of ‘just take Vitamin A’ and ‘give individuals the freedom to choose’ all whilst telling them vaccines can cause autism. How many more people need to die from this absurdity?” the analysts wrote.

Lutnick stepped down as chairman and CEO of Cantor Fitzgerald in February after he was confirmed as the Secretary of Commerce. Lutnick led the investment bank for 40 years.

Continue Reading

Finance

Treasury Yields Rise as Fed Cut Expectations Shift

Published

on

Treasury Yields Rise as Fed Cut Expectations Shift

Fixed-income markets recorded significant re-pricing during the week ending July 25, 2026, as a convergence of strong labor market metrics and surging energy costs drove U.S. Treasury yields higher across all maturities. The benchmark 10-year Treasury yield climbed toward 4.70%, reaching its highest point in several months. Institutional bond investors rapidly adjusted portfolio durations as expectations for near-term interest rate cuts by the Federal Reserve faded in response to inflation concerns.

The upward shift in sovereign yields reflects a broader fundamental reassessment of global monetary policy. Earlier in the quarter, money markets had priced in a series of rate reductions designed to support economic activity. However, with initial jobless claims falling to 187,000 and crude oil breaching $100 per barrel, fixed-income traders are pricing in a ‘higher-for-longer’ interest rate environment. The inversion between short-term Treasury bills and long-term bonds narrowed, indicating a shift toward term premium expansion.

Rising Treasury yields present both challenges and opportunities for institutional wealth managers. While commercial lenders and mortgage origination volumes face headwinds from elevated borrowing costs, fixed-income investors are locking in attractive real yields on high-quality sovereign and investment-grade corporate bonds. Institutional debt issuers, conversely, are recalibrating their capital structures, opting for shorter-term refinancing instruments or private credit facilities to avoid committing to elevated long-term coupon rates.

Navigating the current bond market landscape demands strict duration management and credit selection. Wealth advisors recommend maintaining flexible fixed-income allocations, combining short-duration Treasuries with inflation-protected securities (TIPS) to shield capital against potential energy-driven inflation spikes while earning dependable nominal income.

Continue Reading

Finance

Private Credit Expansion Transforms Corporate Loans

Published

on

Private Credit Expansion Transforms Corporate Loans

Private credit markets reached a pivotal milestone during the week ending July 25, 2026, as non-bank direct lending consortiums captured a record share of middle-market corporate debt originations. With commercial banks maintaining conservative credit standards and public bond yields remaining elevated, corporate borrowers are increasingly turning to private fund managers for customized capital solutions. This expansion marks a permanent structural shift in enterprise finance, establishing private credit as a primary pillar of institutional corporate liquidity.

The acceleration of private credit deals is driven by speed, deal certainty, and flexible terms. Unlike traditional syndicated bank loans that require lengthy underwriting, credit rating approvals, and public roadshows, private direct lenders can structure tailored financing packages within days. Middle-market firms facing upcoming debt maturities are utilizing private debt facilities to execute recapitalizations, strategic acquisitions, and growth capital deployments without risking execution delay in public markets.

However, financial regulators and central bank supervisors are scrutinizing the sector’s rapid growth. Supervisory agencies are evaluating potential systemic risks associated with non-bank leverage, valuation transparency, and liquidity mismatches during economic downturns. Despite regulatory interest, major pension funds, insurance firms, and sovereign wealth entities continue to expand capital allocations to private credit funds, attracted by reliable floating-rate yields that outperform public fixed-income benchmarks.

As private credit matures into a dominant asset class, corporate chief financial officers must evaluate non-bank lenders alongside traditional banking relationships. Direct lending partnerships provide valuable balance sheet resilience, enabling companies to secure flexible financing terms even during periods of public market turbulence.

Continue Reading

Finance

Tokenized Debt Shifts How Corporate Manage Short Term Liquidity

Published

on

Tokenized Debt Shifts Corporate Liquidity

The landscape of institutional debt markets is undergoing a profound structural shift on July 21, 2026, as major corporate issuers and commercial banks rapidly accelerate the deployment of tokenized debt instruments. Data published by leading capital market consortiums indicates that primary issuances of digital commercial paper and tokenized corporate bonds have reached record volumes this month. By moving legacy debt origination, underwriting, and secondary distribution onto permissioned distributed ledgers, corporate treasurers are unlocking unprecedented operational flexibility and instantaneous cross-border liquidity.

The adoption of tokenized debt is fundamentally altering how enterprise balance sheets manage short-term liquidity needs. Traditional corporate bond settlement cycles historically required multi-day clearing processes involving numerous intermediaries, custodial entities, and clearinghouses. Through programmable smart contracts on distributed ledgers, issuers can now execute atomic settlement—enabling continuous, 24/7 access to institutional capital pools. This instantaneous clearing mechanism drastically reduces counterparty risk, eliminates costly settlement friction, and allows treasury teams to dynamically optimize working capital in real time.

A major catalyst driving this institutional migration is the establishment of comprehensive digital asset regulatory frameworks across major financial hubs. Clear legal guidelines regarding ledger-based securities ownership have provided institutional compliance officers with the regulatory confidence necessary to transition multi-billion-dollar liquidity facilities onto digital platforms. Furthermore, the integration of automated regulatory reporting directly into token smart contracts simplifies ongoing compliance audits, ensuring that secondary market trades automatically enforce investor accreditation limits and tax withholding requirements.

For chief financial officers and institutional portfolio managers, tokenized debt represents a fundamental evolution in fixed-income strategy. Companies that embrace ledger-based debt structures gain direct access to a broader, global base of digital-native institutional investors while substantially reducing borrowing overhead. As ledger interoperability continues to improve across global exchanges, tokenized debt is poised to become the standard infrastructure for global corporate finance.

Continue Reading

Trending